CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 79,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the transaction, the chief executive officer directly owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, December 4th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $18.82, for a total transaction of $470,500.00.
• On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.59, for a total transaction of $414,750.00.
• On Friday, November 21st, Xingjuan Chao sold 50,000 shares of CeriBell stock. The stock was sold at an average price of $15.13, for a total transaction of $756,500.00.

CeriBell Price Performance

Shares of CBLL stock traded up $1.10 during mid-day trading on Wednesday, hitting $22.83. 677,591 shares of the stock were exchanged, compared to its average volume of 556,048. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The firm has a fifty day moving average of $17.33 and a 200 day moving average of $14.97. The company has a market cap of $846.99 million, a PE ratio of -15.12 and a beta of 1.02.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. Research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently modified their holdings of CBLL. Rhumbline Advisers boosted its position in CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after acquiring an additional 3,276 shares during the last quarter. Peregrine Capital Management LLC purchased a new position in CeriBell in the 2nd quarter worth approximately $6,399,000. Emerald Advisers LLC lifted its stake in CeriBell by 3.9% in the 2nd quarter. Emerald Advisers LLC now owns 125,869 shares of the company’s stock worth $2,358,000 after purchasing an additional 4,727 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of CeriBell by 26.1% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 98,185 shares of the company’s stock worth $1,839,000 after purchasing an additional 20,350 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its position in shares of CeriBell by 48.5% in the second quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock valued at $14,927,000 after purchasing an additional 260,116 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Raymond James Financial began coverage on shares of CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target on the stock. Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. TD Cowen cut their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. cut their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.